Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Feb 7, 2014; 20(5): 1139-1146
Published online Feb 7, 2014. doi: 10.3748/wjg.v20.i5.1139
Published online Feb 7, 2014. doi: 10.3748/wjg.v20.i5.1139
When combination therapy isn’t working: Emerging therapies for the management of inflammatory bowel disease
Suneeta Krishnareddy, Arun Swaminath, Mount Sinai School of Medicine, Columbia University Medical Center, New York, NY 10029, United States
Author contributions: All the authors contributed equally to this manuscript.
Correspondence to: Arun Swaminath, Assistant Professor of Medicine, Columbia University, 100 East 77th Street, 2nd Floor, New York, NY 10075, United States. aswaminath@NSHS.edu
Telephone: +1-212-4346785 Fax: +1-212-4346275
Received: September 28, 2013
Revised: November 8, 2013
Accepted: January 6, 2014
Published online: February 7, 2014
Processing time: 145 Days and 19.1 Hours
Revised: November 8, 2013
Accepted: January 6, 2014
Published online: February 7, 2014
Processing time: 145 Days and 19.1 Hours
Core Tip
Core tip: In this paper we critically review recently published literature about these novel therapies, which have been the results of extensive research identifying molecular targets. Several agents have been tested and show promising data, but we focus on vedolizumab, a monoclonal antibody against the α4β7 integrin on lymphocytes, ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, and tofacitinib, an orally administered small molecule targeting Janus-activated kinase. These three agents are most likely to find their way soon to the market and offer significant therapeutic advantages for the management of Crohn’s disease and ulcerative colitis.